News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

CEO and senior executives in Egetis Therapeutics acquire shares

May 17, 2021

Stockholm, Sweden, May 17, 2021. Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that Nicklas Westerholm, CEO, Yilmaz Mahshid, incoming CFO, and Henrik Krook, Vice President Commercial Operations, have acquired shares in the company.

Nicklas Westerholm has bought 10,290 additional shares, Yilmaz Mahshid has bought 30,194 additional shares and Henrik Krook has bought 30,000 additional shares. Their respective total holdings now amount to 37,715, 156,000 and 73,955 shares in addition to warrants and employee stock options.

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]